BMS-932481 (2-30 mg/kg, po, single dose) reduces the levels of Aβ1-42 and Aβ1-40, increases levels of Aβ1-38 and Aβ1-37, without changing overall amounts of Aβ peptides in dog models[1].
BMS-932481 (2.5-15 mg/kg, iv, single dose) exhibits moderate brain penetration with brain-to-plasma ratio and AUCbrain to AUCplasma ratio of about 0.23 and 0.6 in Sprague-Dawley rats[1].
| Animal Model: | Beague dog model[1] |
| Dosage: | 2-30 mg/kg |
| Administration: | po, single dose |
| Result: | Reduced levels of Aβ1-42 and Aβ1- 40 of 65% with 30 mg/kg dose, increased levels of Aβ1-38 and Aβ1-37 by 1.8 and 5 fold. |
